Individualized Approaches Are Needed for Optimized Blood Cultures
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Many strategies and technologies are available to improve blood culture (BC)-based diagnostics. The ideal approach to BCs varies between healthcare institutions. Institutions need to examine clinical needs and practices in order to optimize BC-based diagnostics for their site. Before laboratories consider offering rapid matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-ToF MS) or expensive rapid panel-based molecular BC diagnostics, they should optimize preanalytical, analytical, and postanalytical processes and procedures surrounding BC systems. Several factors need to be considered, including local resistance rates, antibiotic prescribing patterns, patient- and provider-types, laboratory staffing, and personnel available to liaise with clinicians to optimize antibiotic use. While there is much excitement surrounding new high-technology diagnostics, cost-neutral benefits can be realized by optimizing existing strategies and using available tools in creative ways. Rapid BC diagnostics should be implemented in a manner that optimizes impact. Strategies to optimize these BC diagnostics in individual laboratories are presented here.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109 · cited 1×
“The first is that early, effective treatment of bloodstream infection is ideal [1].”
BackgroundBanerjee, R., Teng, C. B., Cunningham, S. A., Ihde, S. M., Steckelberg, J. M., Moriarty, J. P., Shah, N. D., Mandrekar, J. N., & Patel, R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ447 · Cited by 570 · cited 4×
“resistance determinant interrogated, blaKPC, was not identified in our study [28].”
BackgroundSelf-citationLim, S. H., Mix, S., Xu, Z., Taba, B., Budvytiene, I., Berliner, A. N., Queralto, N., Churi, Y. S., Huang, R. S., Eiden, M., et al. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02377-13 · Cited by 66 · cited 1×
“but “in-bottle” microbial identification, is being developed [40].”
Background
Cited by
Doern, G. V., Carroll, K. C., Diekema, D. J., Garey, K. W., Rupp, M. E., Weinstein, M. P., & Sexton, D. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00009-19 · Cited by 313
Syndromic Panel-Based Testing in Clinical Microbiology
Ramanan, P., Bryson, A. L., Binnicker, M. J., Pritt, B. S., & Patel, R. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00024-17 · Cited by 308
“, Clostridium difficile-associated diarrhea, selection of drug resistance, and increased patient costs) (4).”
BackgroundSelf-citationAntimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach
Bassetti, M., Poulakou, G., Ruppe, E., Bouza, E., Van Hal, S. J., & Brink, A. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4878-x · Cited by 277
Rello, J., van Engelen, T. S. R., Alp, E., Calandra, T., Cattoir, V., Kern, W. V., Netea, M. G., Nseir, S., Opal, S. M., van de Veerdonk, F. L., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.03.011 · Cited by 143
Diagnostic Stewardship: Opportunity for a Laboratory–Infectious Diseases Partnership
Patel, R., & Fang, F. C. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy077 · Cited by 127
Self-citationMorquin, D., Lejeune, J., Agostini, C., Godreuil, S., Reynes, J., Le Moing, V., & Lamy, B. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciad744 · Cited by 9
Metadata
- Authors
- Banerjee, R., Özenci, V., & Patel, R.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-08-23
- Volume
- 63
- Issue
- 10
- Pages
- 1332-1339
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2546151205
- Cited by
- 60
- References
- 3
- FWCI
- 8.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.